Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Apr 27, 2023 7:19pm
153 Views
Post# 35418204

RE:RE:RE:RE:New Data Format

RE:RE:RE:RE:New Data Format

enriquesuave wrote: Th KM curve includes the 12 undertreated patients as it's the same data as Nvember.and shows 28% CR at 450 days.  If we removed it we would get 67% CR

 

At this point in time, there are 19 active trial patients, 12 of whom are CR.  There are currently 8 CRs at 450 days.  Discounting the first 12 undertreated, if the current 12 remain CR until the 450 day endpoint, that would generously put us at 20 of 44 patients (or a 45% 12 month durable response rate).  

Based on current trends & my brief analysis for the "actively participating" patients (which excludes the first 12), the overall durable response % is likely going to be in the 30%+ range.  The reported 450 day 67% CR fails to account for those who fell out of the trial prior to the 450 day assessment (i.e. due to being a non-responder or for other individual reasons).  All imo.

<< Previous
Bullboard Posts
Next >>